Trevi Therapeutics Statistics
Total Valuation
TRVI has a market cap or net worth of $1.83 billion. The enterprise value is $1.51 billion.
| Market Cap | 1.83B |
| Enterprise Value | 1.51B |
Important Dates
The next estimated earnings date is Thursday, November 12, 2026, after market close.
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TRVI has 142.48 million shares outstanding. The number of shares has increased by 26.95% in one year.
| Current Share Class | 142.48M |
| Shares Outstanding | 142.48M |
| Shares Change (YoY) | +26.95% |
| Shares Change (QoQ) | +11.13% |
| Owned by Insiders (%) | 0.70% |
| Owned by Institutions (%) | 92.47% |
| Float | 118.32M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 5.68 |
| P/TBV Ratio | 5.69 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 37.28, with a Debt / Equity ratio of 0.00.
| Current Ratio | 37.28 |
| Quick Ratio | 36.68 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -19.66% and return on invested capital (ROIC) is -14.28%.
| Return on Equity (ROE) | -19.66% |
| Return on Assets (ROA) | -13.82% |
| Return on Invested Capital (ROIC) | -14.28% |
| Return on Capital Employed (ROCE) | -18.51% |
| Weighted Average Cost of Capital (WACC) | 9.66% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.50M |
| Employee Count | 34 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -71,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +23.84% in the last 52 weeks. The beta is 0.98, so TRVI's price volatility has been similar to the market average.
| Beta (5Y) | 0.98 |
| 52-Week Price Change | +23.84% |
| 50-Day Moving Average | 15.52 |
| 200-Day Moving Average | 14.27 |
| Relative Strength Index (RSI) | 37.97 |
| Average Volume (20 Days) | 2,835,044 |
Short Selling Information
The latest short interest is 14.64 million, so 10.27% of the outstanding shares have been sold short.
| Short Interest | 14.64M |
| Short Previous Month | 12.07M |
| Short % of Shares Out | 10.27% |
| Short % of Float | 12.37% |
| Short Ratio (days to cover) | 9.10 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -59.56M |
| Pretax Income | -51.18M |
| Net Income | -51.11M |
| EBITDA | -59.42M |
| EBIT | -59.56M |
| Earnings Per Share (EPS) | -$0.35 |
Balance Sheet
The company has $318.87 million in cash and $605,000 in debt, with a net cash position of $318.27 million or $2.23 per share.
| Cash & Cash Equivalents | 318.87M |
| Total Debt | 605,000 |
| Net Cash | 318.27M |
| Net Cash Per Share | $2.23 |
| Equity (Book Value) | 321.51M |
| Book Value Per Share | 2.26 |
| Working Capital | 316.97M |
Cash Flow
In the last 12 months, operating cash flow was -$52.63 million and capital expenditures -$238,000, giving a free cash flow of -$52.87 million.
| Operating Cash Flow | -52.63M |
| Capital Expenditures | -238,000 |
| Depreciation & Amortization | 137,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -52.87M |
| FCF Per Share | -$0.37 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TRVI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -26.95% |
| Shareholder Yield | -26.95% |
| Earnings Yield | -2.80% |
| FCF Yield | -2.89% |
Analyst Forecast
The average price target for TRVI is $28.18, which is 119.64% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $28.18 |
| Price Target Difference | 119.64% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |